Why It Matters

Deep Mile Networks has registered its first lobbying effort through MJL Ventures LLC, according to a new lobbying registration disclosure filed in June 2026. The firm is now lobbying on defense and medical research issues as Congress weighs significant spending and regulatory decisions in both areas.

Deep Mile Networks appears to be a first-time entrant into federal lobbying, hiring MJL Ventures LLC to represent its interests on Defense and Medical/Disease Research/Clinical Labs issues. The company's decision to engage in congressional lobbying comes as lawmakers debate major defense spending bills and clinical trial modernization efforts that could reshape how medical research operates and how defense dollars flow.

The timing suggests the organization is positioning itself ahead of key policy debates. Congress is actively advancing major defense legislation this year, and multiple bills addressing clinical trial access and laboratory reimbursements remain under review. The lobbying registration disclosure provides the first public indication of Deep Mile Networks' federal policy priorities.

Broader Context

Congress has been active on both fronts where Deep Mile Networks is now lobbying. On defense, lawmakers passed the FY26 National Defense Authorization Act (NDAA) in December 2025, authorizing $900 billion for the Department of Defense, $8 billion more than requested. The legislation included a 3.8% military pay raise and provisions like the Protect Our Bases Act, which strengthens foreign investment reviews near military sites, and the Foreign Investment Guardrails to Help Thwart (FIGHT) China Act, which establishes guardrails on outbound U.S. investment to China.

On the medical research side, Congress has pursued multiple initiatives. The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, introduced in September 2025, sought to prevent cuts of up to 15% to Medicare reimbursements for approximately 800 clinical lab tests. The National Institutes of Health (NIH) Clinical Trial Integrity Act, introduced in December 2025, required the NIH to develop measurable recruitment goals and reduce barriers to trial participation. Most recently, Sens. Tim Scott and MarkWarner introduced the Clinical Trial Modernization Act of 2026 in April, designed to expand access for underrepresented communities in clinical trials.

The Bottom Line

Deep Mile Networks' entry into federal lobbying reflects the ongoing legislative activity in defense spending and clinical research policy. The new lobbyist registration positions the organization to engage with Congress on issues where multiple bills and appropriations decisions remain in flux.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article